Literature DB >> 15080313

Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.

Robert C Gosselin1, William E Dager, Jeffrey H King, Kim Janatpour, Kathleen Mahackian, Edward C Larkin, John T Owings.   

Abstract

Direct thrombin inhibitors (DTIs) represent a new class of promising anticoagulation agents. The DTIs frequently are used to provide initial anticoagulation, with long-term therapy requiring eventual transition to coumarins. Unfortunately, DTIs not only prolong the activated partial thromboplastin time but also can affect international normalized ratio (INR) values. We approximated the DTI effect on INRs by each drug to pooled plasma at concentrations between 0.1 and 1.2 microg/mL. We then concurrently tested these samples using 14 prothrombin time (PT) reagents. By using repeated measures analysis of variance, we found significant differences (P < .05) between the median INRs for lepirudin and argatroban for all PT reagents, between lepirudin and bivalirudin for all reagents except PT-Fibrinogen HS Plus (P = .07), and between bivalirudin and argatroban for all reagents except Thromborel S (P = .05). The DTI effect on INRs was dependent on drug, drug concentration, and reagent. Argatroban had the most effect on INRs, while lepirudin had the least effect. Reagents with a lower international sensitivity index were less affected by DTI; ThromboMax HS was the least sensitive PT reagent to any DTI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080313     DOI: 10.1309/D79K-4YG7-8NTN-YY38

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Clots Are Potent Triggers of Inflammatory Cell Gene Expression: Indications for Timely Fibrinolysis.

Authors:  Robert A Campbell; Adriana Vieira-de-Abreu; Jesse W Rowley; Zechariah G Franks; Bhanu Kanth Manne; Matthew T Rondina; Larry W Kraiss; Jennifer J Majersik; Guy A Zimmerman; Andrew S Weyrich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-03       Impact factor: 8.311

Review 2.  Monitoring of direct anticoagulants.

Authors:  Susanne Lison; Michael Spannagl
Journal:  Wien Med Wochenschr       Date:  2011-02

3.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

4.  Prospective evaluation of a bivalirudin to warfarin transition nomogram.

Authors:  Benjamin Hohlfelder; Katelyn W Sylvester; Jessica Rimsans; David DeiCicchi; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 5.  Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.

Authors:  Jonathan Bain; Alexander H Flannery; Jeremy Flynn; William Dager
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

Review 6.  Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Zhengwu Sun; Xiaoyan Lan; Shen Li; Hongling Zhao; Zeyao Tang; Yalin Xi
Journal:  Int J Hematol       Date:  2017-06-09       Impact factor: 2.490

7.  Direct Thrombin Inhibitor Resistance and Possible Mechanisms.

Authors:  Maria Cardinale; Michael Ha; Michael H Liu; David P Reardon
Journal:  Hosp Pharm       Date:  2016-12

Review 8.  Heparin induced thrombocytopenia: diagnosis and management update.

Authors:  I Ahmed; A Majeed; R Powell
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

9.  Bivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis.

Authors:  Tariq Janjua; Eric Nussbaum; Jodi Lowary; Virginia Babbini
Journal:  Neurocrit Care       Date:  2013-06       Impact factor: 3.210

10.  Reversible crystallization of argatroban after subcutaneous application in pigs.

Authors:  Mercedes Lopez; Goetz Nowak
Journal:  Thrombosis       Date:  2012-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.